The Cowen analyst has been pounding his shoe on the table for weeks saying MDVN is overvalued. He claims peak enzalutamide sales expectations are $3 billion but that it will be closer to $1 billion. Cites lack of penetration into urologist offices.
Sales are currently running at ~$1 billion per year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.